Form 4 for TVTX Travere Therapeutics, Inc.
Accepted 2025-12-29 00:00:00 ET · period of report 2025-12-24 · accession 0001698262-25-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-12-29 | 2025-12-24 | TVTX | ROTE WILLIAM E. | Chief Research Off | S - Sale+OE | $40.10 | -60.0K | 101.4K | -37% | -$2.41M |
| D | 2025-12-29 | 2025-12-24 | TVTX | ROTE WILLIAM E. | Chief Research Off | M - OptEx | $20.61 | +60.0K | 161.4K | +59% | +$1.24M |
| D | 2025-12-29 | 2025-12-24 | TVTX | ROTE WILLIAM E. | Chief Research Off | M - OptEx | $0.00 | -60.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-24 | S | D | 60,000 | $40.10 | 101,443 | D | — | — | (F3) The weighted average sale price for the transaction reported was $40.103, and the range of prices were between $38.00 and $42.07. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 2 | Common | Common Stock | 2025-12-24 | M | A | 60,000 | $20.61 | 161,443 | D | — | — | (F1) Includes 607 shares of Common Stock that were acquired by the Reporting Person on May 30, 2025, and 595 shares of Common Stock that were acquired by the Reporting Person on November 28, 2025, pursuant to the Issuer's Employee Stock Purchase Plan. |
| 3 | Derivative | Employee stock option (right to buy) | 2025-12-24 | M | D | 60,000 | $0.00 | 0 | D | $20.61 · — to 2027-02-13 | 60,000 Common Stock | (F4) The stock option is fully vested and exercisable. |